Anti-CD137 and PD-1/PD-L1 Antibodies En Route toward Clinical Synergy.
No Thumbnail Available
Identifiers
Date
2017-08-08
Authors
Pérez-Ruiz, Elisabeth
Etxeberria, Iñaki
Rodriguez-Ruiz, Maria E
Melero, Ignacio
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Metrics
Export
Abstract
T-cell costimulation and coinhibition can be respectively exploited by blocking and agonist mAbs. Both strategies can be synergistically combined in mouse models. Early clinical results from combinations of anti-PD-1 mAbs in conjunction with agonist anti-CD137 (4-1BB) mAbs show excellent safety and promising efficacy. Clin Cancer Res; 23(18); 5326-8. ©2017 AACRSee related article by Tolcher et al., p. 5349.
Description
MeSH Terms
Antibodies, Monoclonal
Antineoplastic Agents, Immunological
Antineoplastic Combined Chemotherapy Protocols
B7-H1 Antigen
Clinical Trials, Phase I as Topic
Drug Synergism
Humans
Molecular Targeted Therapy
Neoplasms
Programmed Cell Death 1 Receptor
Treatment Outcome
Tumor Necrosis Factor Receptor Superfamily, Member 9
Antineoplastic Agents, Immunological
Antineoplastic Combined Chemotherapy Protocols
B7-H1 Antigen
Clinical Trials, Phase I as Topic
Drug Synergism
Humans
Molecular Targeted Therapy
Neoplasms
Programmed Cell Death 1 Receptor
Treatment Outcome
Tumor Necrosis Factor Receptor Superfamily, Member 9